4//SEC Filing
Josey John A. 4
Accession 0001776351-25-000003
CIK 0001845337other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 6:15 PM ET
Size
26.6 KB
Accession
0001776351-25-000003
Insider Transaction Report
Form 4
Josey John A.
Director
Transactions
- Award
Stock Option (right to buy Common Stock)
2025-11-06+28,700→ 28,700 totalExercise: $8.99Exp: 2032-06-20→ Common Stock (28,700 underlying) - Award
Stock Option (right to buy Common Stock)
2025-11-06+37,500→ 37,500 totalExercise: $8.99Exp: 2033-06-21→ Common Stock (37,500 underlying) - Disposition to Issuer
Stock Option (right to buy Common Stock)
2025-11-06−32,335→ 0 totalExercise: $13.87Exp: 2034-05-22→ Common Stock (32,335 underlying) - Award
Stock Option (right to buy Common Stock)
2025-11-06+1,181→ 1,181 totalExercise: $8.99Exp: 2031-05-25→ Common Stock (1,181 underlying) - Award
Stock Option (right to buy Common Stock)
2025-11-06+32,335→ 32,335 totalExercise: $8.99Exp: 2034-05-22→ Common Stock (32,335 underlying) - Disposition to Issuer
Stock Option (right to buy Common Stock)
2025-11-06−1,181→ 0 totalExercise: $16.00Exp: 2031-05-25→ Common Stock (1,181 underlying) - Disposition to Issuer
Stock Option (right to buy Common Stock)
2025-11-06−37,500→ 0 totalExercise: $12.69Exp: 2033-06-21→ Common Stock (37,500 underlying) - Disposition to Issuer
Stock Option (right to buy Common Stock)
2025-11-06−63,000→ 0 totalExercise: $16.00Exp: 2031-05-25→ Common Stock (63,000 underlying) - Award
Stock Option (right to buy Common Stock)
2025-11-06+63,000→ 63,000 totalExercise: $8.99Exp: 2031-05-25→ Common Stock (63,000 underlying) - Disposition to Issuer
Stock Option (right to buy Common Stock)
2025-11-06−28,700→ 0 totalExercise: $16.29Exp: 2032-06-20→ Common Stock (28,700 underlying)
Footnotes (3)
- [F1]On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")).
- [F2](Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F3]The options are fully vested.
Documents
Issuer
Day One Biopharmaceuticals, Inc.
CIK 0001845337
Entity typeother
Related Parties
1- filerCIK 0001776351
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 6:15 PM ET
- Size
- 26.6 KB